デュピクセントの世界市場：市場規模、予測、新たな洞察-2032年

デュピクセント（デュピルマブ）はヒト型モノクローナルIgG4抗体で、IL-4とIL-13の受容体複合体に共通するIL-4Raサブユニットに特異的に結合することにより、インターロイキン-4（IL-4）とインターロイキン-13（IL-13）のシグナル伝達を阻害します。デュピルマブは、「i型」レセプターを介してIL-4のシグナル伝達を阻害し、「II型」レセプターを介してIL-4とIL-13の両方のシグナル伝達を阻害します。

IL-4Raを発現する複数の細胞型（例えば、肥満細胞、好酸球、マクロファージ、リンパ球、上皮細胞、杯細胞）と炎症メディエーター（例えば、ヒスタミン、エイコサノイド、ロイコトリエン、サイトカイン、ケモカイン）が炎症に関与しています。デュピルマブでIL4Raを阻害すると、炎症性サイトカイン、ケモカイン、一酸化窒素、IgEの放出を含むIL-4およびIL-13サイトカイン誘発性の炎症反応が抑制されます。

デュピクセントは、アトピー性皮膚炎、喘息、鼻ポリポーシスを伴う慢性鼻副鼻腔炎（CRSwNP）、好酸球性食道炎、結節性痒疹など複数の適応症で承認されています。

当レポートでは、主要7ヶ国、すなわち米国、EU4ヶ国（ドイツ、フランス、イタリア、スペイン）および英国、日本におけるCSU用デュピクセントの2019年～2032年の調査期間における詳細な姿を、CSU用デュピクセントの詳細な説明とともに掲載しています。また、作用機序、用法・用量、規制上のマイルストーンを含む研究開発、その他の開発活動に関する洞察を提供しています。さらに、主要7ヶ国におけるCSUのデュピクセント市場予測分析、SWOT、アナリストの見解、市場競合企業の包括的な概要、CSUの他の新興治療薬に関する概要など、今後の市場評価も含んでいます。

目次

第1章 レポートのイントロダクション

第2章 慢性特発性蕁麻疹（CSU）におけるデュピクセントの概要

• 製品詳細
• 臨床開発
• その他の発達活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 デュピクセント市場評価

• 慢性特発性蕁麻疹（CSU）におけるデュピクセントの市場見通し
• 主要7ヶ国分析
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: DUPIXENT, Clinical Trial Description, 2023
• Table 2: DUPIXENT, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: DUPIXENT Market Size in the 7MM, in USD million (2019-2032)
• Table 6: DUPIXENT Market Size in the US, in USD million (2019-2032)
• Table 7: DUPIXENT Market Size in Germany, in USD million (2019-2032)
• Table 8: DUPIXENT Market Size in France, in USD million (2019-2032)
• Table 9: DUPIXENT Market Size in Italy, in USD million (2019-2032)
• Table 10: DUPIXENT Market Size in Spain, in USD million (2019-2032)
• Table 11: DUPIXENT Market Size in the UK, in USD million (2019-2032)
• Table 12: DUPIXENT Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: DUPIXENT Market Size in the 7MM, USD million (2019-2032)
• Figure 2: DUPIXENT Market Size in the United States, USD million (2019-2032)
• Figure 3: DUPIXENT Market Size in Germany, USD million (2019-2032)
• Figure 4: DUPIXENT Market Size in France, USD million (2019-2032)
• Figure 5: DUPIXENT Market Size in Italy, USD million (2019-2032)
• Figure 6: DUPIXENT Market Size in Spain, USD million (2019-2032)
• Figure 7: DUPIXENT Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: DUPIXENT Market Size in Japan, USD million (2019-2032)

"DUPIXENT Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about DUPIXENT for Chronic Spontaneous Urticaria (CSU) in the seven major markets. A detailed picture of the DUPIXENT for CSU in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the DUPIXENT for CSU. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DUPIXENT market forecast analysis for CSU in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in CSU.

Drug Summary:

DUPIXENT (dupilumab) is a human monoclonal IgG4 antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Ra subunit shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the 'Type I' receptor and both IL-4 and IL-13 signaling through the 'Type II receptor'.

Multiple cell types that express IL-4Ra (e.g., mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, goblet cells) and inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines, chemokines) are involved in inflammation. Blocking IL4Ra with dupilumab inhibits IL-4 and IL-13 cytokine-induced inflammatory responses, including releasing proinflammatory cytokines, chemokines, nitric oxide, and IgE.

DUPIXENT is approved for multiple indications, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis, and prurigo nodularis.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DUPIXENT description, mechanism of action, dosage and administration, research and development activities in Chronic Spontaneous Urticaria (CSU).
• Elaborated details on DUPIXENT regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DUPIXENT research and development activities in CSU across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around DUPIXENT.
• The report contains forecasted sales of DUPIXENT for CSU till 2032.
• Comprehensive coverage of the late-stage emerging therapies for CSU.
• The report also features the SWOT analysis with analyst views for DUPIXENT in CSU.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DUPIXENT Analytical Perspective by DelveInsight

• In-depth DUPIXENT Market Assessment

This report provides a detailed market assessment of DUPIXENT for Chronic Spontaneous Urticaria (CSU) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• DUPIXENT Clinical Assessment

The report provides the clinical trials information of DUPIXENT for Chronic Spontaneous Urticaria (CSU) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Chronic Spontaneous Urticaria (CSU) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DUPIXENT dominance.
• Other emerging products for CSU are expected to give tough market competition to DUPIXENT and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DUPIXENT in CSU.
• Our in-depth analysis of the forecasted sales data of DUPIXENT from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DUPIXENT in CSU.

Key Questions:

• What is the product type, route of administration and mechanism of action of DUPIXENT?
• What is the clinical trial status of the study related to DUPIXENT in Chronic Spontaneous Urticaria (CSU) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DUPIXENT development?
• What are the key designations that have been granted to DUPIXENT for CSU?
• What is the forecasted market scenario of DUPIXENT for CSU?
• What are the forecasted sales of DUPIXENT in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to DUPIXENT for CSU?
• Which are the late-stage emerging therapies under development for the treatment of CSU?

Table of Contents

1. Report Introduction

2. DUPIXENT Overview in Chronic Spontaneous Urticaria (CSU)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. DUPIXENT Market Assessment

• 5.1. Market Outlook of DUPIXENT in Chronic Spontaneous Urticaria (CSU)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of DUPIXENT in the 7MM for Chronic Spontaneous Urticaria (CSU)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of DUPIXENT in the United States for Chronic Spontaneous Urticaria (CSU)
  • 5.3.2. Market Size of DUPIXENT in Germany for Chronic Spontaneous Urticaria (CSU)
  • 5.3.3. Market Size of DUPIXENT in France for Chronic Spontaneous Urticaria (CSU)
  • 5.3.4. Market Size of DUPIXENT in Italy for Chronic Spontaneous Urticaria (CSU)
  • 5.3.5. Market Size of DUPIXENT in Spain for Chronic Spontaneous Urticaria (CSU)
  • 5.3.6. Market Size of DUPIXENT in the United Kingdom for Chronic Spontaneous Urticaria (CSU)
  • 5.3.7. Market Size of DUPIXENT in Japan for Chronic Spontaneous Urticaria (CSU)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options